NCT06800677Active, not recruiting
Methylated Biomarkers Predictive of Endometrial Cancer Risk
Source: ClinicalTrials.gov · Last updated 30 Jan 2025
Brief summary (registry, in English)
The goal of this observational study is to identify endometrial cancer risk predictive biomarkers and to optimise the methodology for their detection and quantification in non-invasive samples.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 31 Jul 2024
- Start date
- 31 Jul 2024
- Primary completion date
- Jun 2026
- Lead sponsor
- University of Manchester
- Diseases
- Endometrial cancer
- NCT number
- NCT06800677
What you commit to
- Study type: Observational
- Planned participants: 200
- From 31 Jul 2024 to the primary completion date, Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Presence of malignancy asides from endometrial cancer
- Undergoing elective hysterectomy for suspected ovarian cancer
Who the study is looking for
- Women aged 45-70 years
- Attending St Mary's Hospital, Manchester for an elective hysterectomy by any route for either the treatment of endometrial cancer or a benign gynaecological condition
- Able to consent to participation in the study
Age in the registry: 45 years to 70 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Manchester University NHS Foundation Trust Coordinator of this site? Confirm its status | Manchester | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.